MedTrace Logo

Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol

NCT01023516 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 615

Last updated 2012-08-03

Study results available
· View outcomes & findings →

Summary

The primary objective is to evaluate the efficacy of AZD9668 compared with placebo in symptomatic COPD patients by assessing the effects on lung function and symptoms of COPD

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

AZD9668

2 x 30 mg oral tablets bd for 12 weeks

DRUG

Placebo

2 x matched placebo to oral tablet bd for 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Piotr Kuna, Professor · Samodzielny Publiczny ZOZ Uniwersytecki Szpital Kliniczny

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • Bulgaria
  • Czechia
  • Hungary
  • Poland
  • Romania
  • Slovakia

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01023516 on ClinicalTrials.gov